A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
Sponsor: Albireo
Listed as NCT04006145, this PHASE2 trial focuses on NAFLD and NASH and remains completed. Sponsored by Albireo, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2026 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albireo
For direct contact, visit the study record on ClinicalTrials.gov .